Editor: What To Know
- In addition, the ‘314 patent serves as the parent patent for current patent applications being prosecuted in both China and Europe.
- NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued ENDRA a new patent, U.
- , supports our strategy to protect ENDRA's intellectual property, lead innovation in the thermoacoustic sector and broaden the potential applications for our proprietary TAEUS® technology for both clinical and non-clinical applications,”.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued ENDRA a new patent, U.S. Patent No. 11266314 (the ‘314 patent) titled “Method and System for Determining a Material Type of an Object of Interest.”
The ‘314 patent protects ENDRA’s method and system for determining a material type by utilizing TAEUS. The patent has potential applications beyond liver measurements and even outside the human body. In addition, the ‘314 patent serves as the parent patent for current patent applications being prosecuted in both China and Europe.
“This newly issued patent, our 24th in the U.S., supports our strategy to protect ENDRA’s intellectual property, lead innovation in the thermoacoustic sector and broaden the potential applications for our proprietary TAEUS® technology for both clinical and non-clinical applications,” stated ENDRA’s Chief Executive Officer Francois Michelon. “We maintain a concerted effort to enhance the defensive and offensive value of our patent portfolio in priority markets. Our global intellectual property portfolio currently stands at 89 assets, which we define as patents in preparation, filed or issued.”
